Serum Biomarkers for Nonalcoholic Fatty Liver Disease: Are We There Yet?

Hepatology - United States
doi 10.1002/hep.28840
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Role of Biomarkers for the Screening of Preeclampsia, Are We There Yet?

Indonesian Journal of Obstetrics and Gynecology
2019English

Corticosteroids for Pneumonia: Are We There Yet?

Respirology
PulmonaryRespiratory Medicine
2013English

Nonalcoholic Fatty Liver Disease

Hypertension
Internal Medicine
2020English

Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease—Is There a Link?

Gastroenterology Research and Practice
HepatologyGastroenterology
2014English

Predicting Delirium: Are We There Yet?

British Journal of Anaesthesia
AnesthesiologyPain Medicine
2017English

Nonalcoholic Fatty Liver Disease: Biomarkers Support Decisions Around Pharmacological Intervention

Hepatology
MedicineHepatology
2016English

Cancer Immunotherapy: Are We There Yet?

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2013English

A Pilot Study of Serum MicroRNAs Panel as Potential Biomarkers for Diagnosis of Nonalcoholic Fatty Liver Disease

PLoS ONE
Multidisciplinary
2014English

Nonalcoholic Fatty Liver Disease

Gastroenterology
HepatologyGastroenterology
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy